Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical’s subsidiary has successfully had its drug registration application for Venlafaxine Hydrochloride Sustained-Release Tablets accepted by China’s National Medical Products Administration. This new drug, aimed at treating depression and generalized anxiety disorder, marks a significant step in Fosun Pharma’s investment in innovative treatments, with approximately RMB 6.17 million already invested in its development.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
